Harrow, Inc. (NASDAQ:HROW – Get Free Report) major shareholder Opaleye Management Inc. purchased 11,715 shares of the stock in a transaction dated Tuesday, April 23rd. The shares were purchased at an average price of $10.29 per share, with a total value of $120,547.35. Following the completion of the acquisition, the insider now owns 3,786,715 shares of the company’s stock, valued at $38,965,297.35. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Opaleye Management Inc. also recently made the following trade(s):
- On Thursday, April 25th, Opaleye Management Inc. acquired 20,000 shares of Harrow stock. The stock was bought at an average cost of $9.97 per share, with a total value of $199,400.00.
- On Friday, April 19th, Opaleye Management Inc. purchased 29,400 shares of Harrow stock. The shares were bought at an average price of $10.56 per share, for a total transaction of $310,464.00.
- On Thursday, March 28th, Opaleye Management Inc. acquired 50,000 shares of Harrow stock. The stock was acquired at an average price of $12.82 per share, with a total value of $641,000.00.
- On Wednesday, March 20th, Opaleye Management Inc. purchased 50,600 shares of Harrow stock. The stock was bought at an average price of $9.65 per share, for a total transaction of $488,290.00.
Harrow Price Performance
Shares of NASDAQ:HROW traded up $0.32 during trading on Tuesday, hitting $10.81. 109,519 shares of the stock were exchanged, compared to its average volume of 430,917. The company has a fifty day moving average price of $11.45 and a two-hundred day moving average price of $10.97. The company has a current ratio of 2.83, a quick ratio of 2.61 and a debt-to-equity ratio of 2.60. The company has a market cap of $382.46 million, a PE ratio of -14.41 and a beta of 0.58. Harrow, Inc. has a 12-month low of $7.60 and a 12-month high of $28.25.
Hedge Funds Weigh In On Harrow
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Harrow in the third quarter valued at about $26,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in Harrow in the 3rd quarter worth about $34,000. China Universal Asset Management Co. Ltd. increased its position in shares of Harrow by 347.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,063 shares of the company’s stock valued at $46,000 after purchasing an additional 3,155 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Harrow by 122.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,073 shares of the company’s stock valued at $90,000 after acquiring an additional 4,440 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in Harrow by 12.7% in the 1st quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company’s stock worth $224,000 after purchasing an additional 1,912 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on HROW shares. Craig Hallum started coverage on Harrow in a research note on Thursday, April 11th. They issued a “buy” rating and a $24.00 price objective on the stock. B. Riley dropped their price objective on Harrow from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd.
View Our Latest Stock Report on HROW
About Harrow
Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Read More
- Five stocks we like better than Harrow
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Garmin Navigates to New Highs Driven By Wearables Trend
- Where Do I Find 52-Week Highs and Lows?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Why Invest in Biotech Stocks
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.